AKT1 and major depressive disorder: Our previous investigation based on network pharmacology revealed that SGKL targets the PI3K/Akt/mTOR pathway, indicating that SGKL might contribute to alleviating depression symptoms through the PI3K/Akt/mTOR pathway.